Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
Terug naar discussie overzicht
Biocartis forum geopend
Volgen
To date, the only FDA approvals in the US have come largely through the efforts of JnJ. The 2017 console, and the RSV cartridge approval were largely JnJs doing. The RSV cartridge was apparently rendered obsolete by competing devices and Biocartis decided to exit the infectious disease market.. I took the 2018 announcement that Biocartis was opening a facility in the JnJ space in Raratan NJ and acquiring 10 JnJ staff as a sign that they would tap JnJ strengths to expedite winning regulatory approvals. This has not been evident. My concern now is that JnJ may looking to acquire BCART on the cheap. If BCART continues on this trajectory the they may need to raise cash again in late 2020 or early 2021. This will be difficult unless the outlook changes. As I mentioned previously, there are many catalysts that can change the trajectory for the better, but the execution needs to improve. There is still a lot of time. Rather than emphasizing the buildup of a US sales force (an expensive proposition), I think BCART needs to emphasize regulatory approvals that will make Idylla eligible for insurance reimbursement. With regulatory approvals, their partners will help sell and they can avoid the advertisement restrictions that are currently constraining marketing in the US. FL
Don't want to come across too negative.but history is littered with companies that brought new technology to market only to have someone else succeed in making it commercially successful (think about the commodore PC). The pathology journals I have read indicate strong support for first line use of Idylla but the business execution does not appear to be capitalizing on this potential. As I've indicated from my experience with GHDX, it can take a while before a critical mass of support is developed that allows commercial traction possible. The partnerships and the technical seminar presentations (especially user testimonials) are critical in developing this support. FL
makyjo schreef op 10 september 2019 16:24 :
Ideaal om NU bij te kopen.
Alleen voor de durvers!!
Want is zeker een andere verhaal dan Thrombogenics. (Oxurion)
Biocartis berichtte vorige week woensdag over een halvering van de oorspronkelijke groeiprognoses. Vorige week woensdag noteerde het aandeel vlak voor de domper nog € 10,28. De groeibijstelling leidde donderdag tot een vrije val naar € 6,98. Zojuist werd € 6,50 op het koersenbord gesignaleerd. De koershistorie van Biocartis toont in 2016 een bodemproces tussen € 6,69 en € 6,59. De relatieve sterkte index raakte vorige week het meest oversold in relatie tot voorgaande oververkochte waarderingen. Traders die zich afvragen wat te doen in deze overwegend afwachtende markt weten dat de beste koopmomenten zich voordoen als het spreekwoordelijke bloed door de straat loopt.
[quote alias=DeZwarteRidder id=11820851 date=201909101526] [...] Ja, J&J en Amgen gaan graag de concurrentie een handje helpen..........!!! [/qu J&J is grootaandeelhouder,en met Amgen is een deal afgesloten. Toch niet onrealistisch dan?
Apparently Fisher has not taken the Idylla Console systems off of its exchange, yet. FLwww.fishersci.com/us/en/catalog/searc...
ronald64 schreef op 11 september 2019 07:00 :
[...]
Biocartis berichtte vorige week woensdag over een halvering van de oorspronkelijke groeiprognoses. Vorige week woensdag noteerde het aandeel vlak voor de domper nog € 10,28. De groeibijstelling leidde donderdag tot een vrije val naar € 6,98. Zojuist werd € 6,50 op het koersenbord gesignaleerd. De koershistorie van Biocartis toont in 2016 een bodemproces tussen € 6,69 en € 6,59. De relatieve sterkte index raakte vorige week het meest oversold in relatie tot voorgaande oververkochte waarderingen. Traders die zich afvragen wat te doen in deze overwegend afwachtende markt weten dat de beste koopmomenten zich voordoen als het spreekwoordelijke bloed door de straat loopt.
Aldus Loef. Inderdaad mooi koopmoment, iedereen die er uit wilde is eruit.
Look0406 schreef op 13 september 2019 11:51 :
[...]
Aldus Loef.
Inderdaad mooi koopmoment, iedereen die er uit wilde is eruit.
Het begint nu wel een zielig afglijden te worden van de koers, waar stopt het...
FDJ30 schreef op 13 september 2019 13:39 :
[...]
Het begint nu wel een zielig afglijden te worden van de koers, waar stopt het...
Ong. 6,5 euro
Nu dubbele bodem rond 6,5 2e bodem lager volume Positieve divergentie
www.fishersci.com/us/en/catalog/searc... The situation with Fisher in the US has become pretty transparent. They continue to market the consoles on the Fisher platform but not the cartridges. The console has received a determination that it is exempted from FDA 510K approval process. But the assay cartridges are approved in the US for research use only RUO designation.. www.globenewswire.com/news-release/20... Trading of Biocartis on the Schwab global platform is suspended on a regulatory violation (SEC Regulation S), This regulation limits the advertising statements that can be made about a product until it has secured approvals. Putting 2+2 together, it is apparent that it is likely that Fisher overstepped the advertising limitation that can be made under the RUO designation. Hence, they can no longer sell the cartridges on the Fisher exchange site. I believe the cartridges came off of the exchange in early July explaining the big US sales miss. I think BCART had no other choice but to internalize the sales so they can strictly control the promotional materials and the sales pitch. This can be corrected with FDA 510K approval of the assay cartridges. The good news is that if a product is truly an advancement, it can be very successful even if it stumbles in the U.S. Possibly due to no fault of its own. I've invested in Novartis for a long time. They brought a diabetes drug called Galvus to the FDA for approval and it got rejected on concerns over early animal testing rashes during the preclinical trials. This happened despite one of the largest Phase III studies ever conducted at the time bearing out the efficacy and the lack of this drug side effect. Galvus went on to become a blockbuster with approvals throughout the world but it never came to market in the US. NVS saw the writing on the wall and withdrew the FDA approval application and never refiled despite the US market being the largest diabetes market in the world.. This opened the door for Merk's competing drug Januvia. My point is that regulatory powers are often applied in ways that are designed to benefit domestic competitors.. Unfortunately it happens throughout the world. However, if the product is a true advancement, it can still do great even with trade barriers that might create temporary stumbles. It is critical to recognize the nature of the impediments and to determine how to best allocate resources given the impediments. The right partners can also make all the difference in gaining regulatory approvals. FL
en.....weg dubbele bodem, waar gaat dat stoppen.. Ik koop nog bij op 6.10 en lager...
PS kan het zijn dat ze de koers in elkaar trappen aangaande een speler die aast op een overname?
Zo, dit hebben we ook alweer gehad Q3 voorbij,koers gehalveerd . Zaterdag 28/09 staat Biocartis op het Biotechpaviljoen, tijdens de dag van de tips (?). Georganiseerd door deVFB.Benieuwd wat hij nu uit z'n nek zal staan lullen,of zend hij z'n kat.
kwaliteit komt altijd bovendrijven, we gaan terug naar aanvaardbare waarden terugkeren de komende weken...
Tomorrow's meeting and the turmoil since the Sept 5 earnings announcement will result in some shakeup in the shareholder base. I expect that some consolidation is occurring as some smaller holders are getting shaken out. The shareholder base is currently widely disseminated such that it would be difficult to acquire BCART without wide shareholder support. Consolidation will reduce the number of holders, such that an acquisition might be easier in the future. I'm not saying anything is imminent, only that the dynamics are likely to be changing. FL
GHDX Conf Call discussion of Biocartis from 13:45 - 17:00. edge.media-server.com/mmc/p/c434qn2q Don't think any of this is new. However, GHDX conference calls express a lot more optimistic tone than the BCART calls. FL
This is starting to hurt. Did I miss something?
FilipVanderAa schreef op 25 september 2019 12:31 :
This is starting to hurt. Did I miss something?
Ja, een hoop geld....!!! Dat komt er van als je in (Belgische) sprookjes gelooft.
Als de koers zo laag blijft ziet het er slecht voor Biocartis, want dan kunnen ze hun converteerbare lening niet aflossen en volgt er waarschijnlijk een gedwongen equity-swap (of erger). Denk aan Nyrstar......
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Koffiekamer
Belastingzaken
Beleggingsfondsen
Beursspel
BioPharma
Daytraders
Garantieproducten
Opties
Technische Analyse
Technische Analyse Software
Vastgoed
Warrants
10 van Tak
4Energy Invest
Aalberts
AB InBev
Abionyx Pharma
Ablynx
ABN AMRO
ABO-Group
Acacia Pharma
Accell Group
Accentis
Accsys Technologies
ACCSYS TECHNOLOGIES PLC
Ackermans & van Haaren
ADMA Biologics
Adomos
AdUX
Adyen
Aedifica
Aegon
AFC Ajax
Affimed NV
ageas
Agfa-Gevaert
Ahold
Air France - KLM
Airspray
Akka Technologies
AkzoNobel
Alfen
Allfunds Group
Allfunds Group
Almunda Professionals (vh Novisource)
Alpha Pro Tech
Alphabet Inc.
Altice
Alumexx ((Voorheen Phelix (voorheen Inverko))
AM
Amarin Corporation
Amerikaanse aandelen
AMG
AMS
Amsterdam Commodities
AMT Holding
Anavex Life Sciences Corp
Antonov
Aperam
Apollo Alternative Assets
Apple
Arcadis
Arcelor Mittal
Archos
Arcona Property Fund
arGEN-X
Aroundtown SA
Arrowhead Research
Ascencio
ASIT biotech
ASMI
ASML
ASR Nederland
ATAI Life Sciences
Atenor Group
Athlon Group
Atrium European Real Estate
Auplata
Avantium
Axsome Therapeutics
Azelis Group
Azerion
B&S Group
Baan
Ballast Nedam
BALTA GROUP N.V.
BAM Groep
Banco de Sabadell
Banimmo A
Barco
Barrick Gold
BASF SE
Basic-Fit
Basilix
Batenburg Beheer
BE Semiconductor
Beaulieulaan
Befimmo
Bekaert
Belgische aandelen
Beluga
Beter Bed
Bever
Binck
Biocartis
Biophytis
Biosynex
Biotalys
Bitcoin en andere cryptocurrencies
bluebird bio
Blydenstijn-Willink
BMW
BNP Paribas S.A.
Boeing Company
Bols (Lucas Bols N.V.)
Bone Therapeutics
Borr Drilling
Boskalis
BP PLC
bpost
Brand Funding
Brederode
Brill
Bristol-Myers Squibb
Brunel
C/Tac
Campine
Canadese aandelen
Care Property Invest
Carmila
Carrefour
Cate, ten
CECONOMY
Celyad
CFD's
CFE
CGG
Chinese aandelen
Cibox Interactive
Citygroup
Claranova
CM.com
Co.Br.Ha.
Coca-Cola European Partners
Cofinimmo
Cognosec
Colruyt
Commerzbank
Compagnie des Alpes
Compagnie du Bois Sauvage
Connect Group
Continental AG
Corbion
Core Labs
Corporate Express
Corus
Crescent (voorheen Option)
Crown van Gelder
Crucell
CTP
Curetis
CV-meter
CVC Capital Partners
Cyber Security 1 AB
Cybergun
D'Ieteren
D.E Master Blenders 1753
Deceuninck
Delta Lloyd
DEME
Deutsche Cannabis
DEUTSCHE POST AG
Dexia
DGB Group
DIA
Diegem Kennedy
Distri-Land Certificate
DNC
Dockwise
DPA Flex Group
Draka Holding
DSC2
DSM
Duitse aandelen
Dutch Star Companies ONE
Duurzaam Beleggen
DVRG
Ease2pay
Ebusco
Eckert-Ziegler
Econocom Group
Econosto
Edelmetalen
Ekopak
Elastic N.V.
Elia
Endemol
Energie
Energiekontor
Engie
Envipco
Erasmus Beursspel
Eriks
Esperite (voorheen Cryo Save)
EUR/USD
Eurobio
Eurocastle
Eurocommercial Properties
Euronav
Euronext
Euronext
Euronext.liffe Optiecompetitie
Europcar Mobility Group
Europlasma
EVC
EVS Broadcast Equipment
Exact
Exmar
Exor
Facebook
Fagron
Fastned
Fingerprint Cards AB
First Solar Inc
FlatexDeGiro
Floridienne
Flow Traders
Fluxys Belgium D
FNG (voorheen DICO International)
Fondsmanager Gezocht
ForFarmers
Fountain
Frans Maas
Franse aandelen
FuelCell Energy
Fugro
Futures
FX, Forex, foreign exchange market, valutamarkt
Galapagos
Gamma
Gaussin
GBL
Gemalto
General Electric
Genfit
Genmab
GeoJunxion
Getronics
Gilead Sciences
Gimv
Global Graphics
Goud
GrandVision
Great Panther Mining
Greenyard
Grolsch
Grondstoffen
Grontmij
Guru
Hagemeyer
HAL
Hamon Groep
Hedge funds: Haaien of helden?
Heijmans
Heineken
Hello Fresh
HES Beheer
Hitt
Holland Colours
Homburg Invest
Home Invest Belgium
Hoop Effektenbank, v.d.
Hunter Douglas
Hydratec Industries (v/h Nyloplast)
HyGear (NPEX effectenbeurs)
HYLORIS
Hypotheken
IBA
ICT Automatisering
Iep Invest (voorheen Punch International)
Ierse aandelen
IEX Group
IEX.nl Sparen
IMCD
Immo Moury
Immobel
Imtech
ING Groep
Innoconcepts
InPost
Insmed Incorporated (INSM)
IntegraGen
Intel
Intertrust
Intervest Offices & Warehouses
Intrasense
InVivo Therapeutics Holdings Corp (NVIV)
Isotis
JDE PEET'S
Jensen-Group
Jetix Europe
Johnson & Johnson
Just Eat Takeaway
Kardan
Kas Bank
KBC Ancora
KBC Groep
Kendrion
Keyware Technologies
Kiadis Pharma
Kinepolis Group
KKO International
Klépierre
KPN
KPNQwest
KUKA AG
La Jolla Pharmaceutical
Lavide Holding (voorheen Qurius)
LBC
LBI International
Leasinvest
Logica
Lotus Bakeries
Macintosh Retail Group
Majorel
Marel
Mastrad
Materialise NV
McGregor
MDxHealth
Mediq
Melexis
Merus Labs International
Merus NV
Microsoft
Miko
Mithra Pharmaceuticals
Montea
Moolen, van der
Mopoli
Morefield Group
Mota-Engil Africa
MotorK
Moury Construct
MTY Holdings (voorheen Alanheri)
Nationale Bank van België
Nationale Nederlanden
NBZ
Nedap
Nedfield
Nedschroef
Nedsense Enterpr
Nel ASA
Neoen SA
Neopost
Neovacs
NEPI Rockcastle
Netflix
New Sources Energy
Neways Electronics
NewTree
NexTech AR Solutions
NIBC
Nieuwe Steen Investments
Nintendo
Nokia
Nokia OYJ
Nokia Oyj
Novacyt
NOVO-NORDISK AS
NPEX
NR21
Numico
Nutreco
Nvidia
NWE Nederlandse AM Hypotheek Bank
NX Filtration
NXP Semiconductors NV
Nyrstar
Nyxoah
Océ
OCI
Octoplus
Oil States International
Onconova Therapeutics
Ontex
Onward Medical
Onxeo SA
OpenTV
OpGen
Opinies - Tilburg Trading Club
Opportunty Investment Management
Orange Belgium
Oranjewoud
Ordina Beheer
Oud ForFarmers
Oxurion (vh ThromboGenics)
P&O Nedlloyd
PAVmed
Payton Planar Magnetics
Perpetuals, Steepeners
Pershing Square Holdings Ltd
Personalized Nursing Services
Pfizer
Pharco
Pharming
Pharnext
Philips
Picanol
Pieris Pharmaceuticals
Plug Power
Politiek
Porceleyne Fles
Portugese aandelen
PostNL
Priority Telecom
Prologis Euro Prop
ProQR Therapeutics
PROSIEBENSAT.1 MEDIA SE
Prosus
Proximus
Qrf
Qualcomm
Quest For Growth
Rabobank Certificaat
Randstad
Range Beleggen
Recticel
Reed Elsevier
Reesink
Refresco Gerber
Reibel
Relief therapeutics
Renewi
Rente en valuta
Resilux
Retail Estates
RoodMicrotec
Roularta Media
Royal Bank Of Scotland
Royal Dutch Shell
RTL Group
RTL Group
S&P 500
Samas Groep
Sapec
SBM Offshore
Scandinavische (Noorse, Zweedse, Deense, Finse) aandelen
Schuitema
Seagull
Sequana Medical
Shurgard
Siemens Gamesa
Sif Holding
Signify
Simac
Sioen Industries
Sipef
Sligro Food Group
SMA Solar technology
Smartphoto Group
Smit Internationale
Snowworld
SNS Fundcoach Beleggingsfondsen Competitie
SNS Reaal
SNS Small & Midcap Competitie
Sofina
Softimat
Solocal Group
Solvac
Solvay
Sopheon
Spadel
Sparen voor later
Spectra7 Microsystems
Spotify
Spyker N.V.
Stellantis
Stellantis
Stern
Stork
Sucraf A en B
Sunrun
Super de Boer
SVK (Scheerders van Kerchove)
Syensqo
Systeem Trading
Taiwan Semiconductor Manufacturing Company (TSMC)
Technicolor
Tele Atlas
Telegraaf Media
Telenet Groep Holding
Tencent Holdings Ltd
Tesla Motors Inc.
Tessenderlo Group
Tetragon Financial Group
Teva Pharmaceutical Industries
Texaf
Theon International
TherapeuticsMD
Thunderbird Resorts
TIE
Tigenix
Tikkurila
TINC
TITAN CEMENT INTERNATIONAL
TKH Group
TMC
TNT Express
TomTom
Transocean
Trigano
Tubize
Turbo's
Twilio
UCB
Umicore
Unibail-Rodamco
Unifiedpost
Unilever
Unilever
uniQure
Unit 4 Agresso
Univar
Universal Music Group
USG People
Vallourec
Value8
Value8 Cum Pref
Van de Velde
Van Lanschot
Vastned
Vastned Retail Belgium
Vedior
VendexKBB
VEON
Vermogensbeheer
Versatel
VESTAS WIND SYSTEMS
VGP
Via Net.Works
Viohalco
Vivendi
Vivoryon Therapeutics
VNU
VolkerWessels
Volkswagen
Volta Finance
Vonovia
Vopak
Warehouses
Wave Life Sciences Ltd
Wavin
WDP
Wegener
Weibo Corp
Wereldhave
Wereldhave Belgium
Wessanen
What's Cooking
Wolters Kluwer
X-FAB
Xebec
Xeikon
Xior
Yatra Capital Limited
Zalando
Zenitel
Zénobe Gramme
Ziggo
Zilver - Silver World Spot (USD)
Premium
Word nu abonnee van IEX en krijg onbeperkt toegang tot onze (koop)tips en succesvolle modelportefeuilles. Nu 3 maanden voor slechts €19,95! Profiteer van 58% korting!
Word abonnee